JP Morgan Maintains Overweight on Akero Therapeutics, Raises Price Target to $62
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Eric Joseph maintains an Overweight rating on Akero Therapeutics (NASDAQ:AKRO) and raises the price target from $49 to $62.
September 05, 2023 | 4:59 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
JP Morgan maintains an Overweight rating on Akero Therapeutics and raises the price target from $49 to $62.
The news of JP Morgan maintaining an Overweight rating and raising the price target for Akero Therapeutics is likely to be seen as a positive signal by the market, potentially leading to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100